<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2172">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01729156</url>
  </required_header>
  <id_info>
    <org_study_id>C11palmitatMetformin</org_study_id>
    <nct_id>NCT01729156</nct_id>
  </id_info>
  <brief_title>Effects of Metformin on Hepatic FFA Metabolism</brief_title>
  <official_title>Effects of Metformin on Hepatic Free Fatty Acid Metabolism in Patients Diagnosed With Type 2 Diabetes: A C11 PET Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Christian Gormsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Metformin treatment has beneficial effects on both glucose and lipid metabolism.&#xD;
      Whereas there is general agreement that the blood glucose lowering effect of metformin&#xD;
      results from inhibition of hepatic gluconeogenesis, it is less clear exactly how the drug&#xD;
      lowers blood triglyceride concentration. There are indications that it enhances hepatic free&#xD;
      fatty acid (FFA) oxidation thus diminishing substrate for reesterification and resecretion as&#xD;
      very-low-density-lipoprotein (VLDL) triglycerides (TG). However, the liver is not easily&#xD;
      accessible for sampling in humans and data on the clinical effects of metformin in the liver&#xD;
      are therefore lacking. This may change due to the increasing use of the positron emission&#xD;
      tomography (PET) technique. Using PET isotopes (11C or 18F) coupled to either palmitate or a&#xD;
      fatty acid analogue, it is possible to non-invasively measure hepatic fatty acid handling.&#xD;
&#xD;
      Aim: To determine how 3 months metformin treatment (1000 mg twice daily) affects hepatic&#xD;
      lipid and glucose metabolism in patients with newly diagnosed type 2 diabetes.&#xD;
&#xD;
      Design: Randomized, placebo controlled, double-blind parallel study with patients receiving&#xD;
      either metformin or placebo. A control group of BMI and age-matched non-diabetic individuals&#xD;
      will receive metformin for 3 months.&#xD;
&#xD;
      Hypothesis: Metformin lowers VLDL-TG secretion and circulating triglycerides by increasing&#xD;
      hepatic fatty acid oxidation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 5, 2017</completion_date>
  <primary_completion_date type="Actual">May 5, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Fatty Acid Oxidation</measure>
    <time_frame>90 days</time_frame>
    <description>Hepatic fatty acid oxidation assessed by dynamic C11-palmitate PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Fatty Acid Reesterification</measure>
    <time_frame>90 days</time_frame>
    <description>Hepatic fatty acid reesterification assessed by C11-palmitate PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Fatty Acid Uptake</measure>
    <time_frame>90 days</time_frame>
    <description>Hepatic fatty acid uptake assessed by C11-palmitate PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VLDL-TG Secretion</measure>
    <time_frame>90 days</time_frame>
    <description>Hepatic VLDL-TG secretion assessed by [1-14C] VLDL tracer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole Body Glucose Rd</measure>
    <time_frame>90 days</time_frame>
    <description>Whole body basal glucose metabolism assessed by [3-3H]glucose tracer kinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatty Acid Turnover</measure>
    <time_frame>90 days</time_frame>
    <description>Fatty acid turnover assessed as whole body C11-palmitate turnover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG Oxidation</measure>
    <time_frame>90 days</time_frame>
    <description>VLDL-TG oxidation assessed by 14C carbon dioxide (CO2) in exhaled breath</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin &quot;Sandoz&quot;, 1000 mg twice daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg metformin twice daily in 3 months</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin &quot;Sandoz&quot; 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets twice daily in 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recently diagnosed type 2 diabetes&#xD;
&#xD;
          -  Age 50-70 years&#xD;
&#xD;
          -  BMI&lt;40&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin treatment&#xD;
&#xD;
          -  NASH (non alcoholic steatohepatitis)&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  HbA1C&gt;8.5 %&#xD;
&#xD;
          -  Chronic or acute pancreatitis&#xD;
&#xD;
          -  Alcohol or medicine abuse&#xD;
&#xD;
          -  Allergy towards metformin&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Severe obesity (weight &gt;130 kilogram)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars C Gormsen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>November 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2012</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2019</results_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Christian Gormsen</investigator_full_name>
    <investigator_title>Senior Registrar, MD PhD</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Hepatic fatty acid oxidation</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 4, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT01729156/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls</title>
          <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
        </group>
        <group group_id="P3">
          <title>Metformin</title>
          <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Controls</title>
          <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
        </group>
        <group group_id="B3">
          <title>Metformin</title>
          <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="6"/>
                    <measurement group_id="B2" value="60" spread="5"/>
                    <measurement group_id="B3" value="64" spread="5"/>
                    <measurement group_id="B4" value="62" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="4.1"/>
                    <measurement group_id="B2" value="31.2" spread="4.3"/>
                    <measurement group_id="B3" value="30.3" spread="5.7"/>
                    <measurement group_id="B4" value="29.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1C</title>
          <units>mmol/mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="3"/>
                    <measurement group_id="B2" value="45" spread="6"/>
                    <measurement group_id="B3" value="51" spread="6"/>
                    <measurement group_id="B4" value="44" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Fatty Acid Oxidation</title>
        <description>Hepatic fatty acid oxidation assessed by dynamic C11-palmitate PET</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Fatty Acid Oxidation</title>
          <description>Hepatic fatty acid oxidation assessed by dynamic C11-palmitate PET</description>
          <units>micromol/ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.024"/>
                    <measurement group_id="O2" value="0.045" spread="0.024"/>
                    <measurement group_id="O3" value="0.042" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Fatty Acid Reesterification</title>
        <description>Hepatic fatty acid reesterification assessed by C11-palmitate PET</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Fatty Acid Reesterification</title>
          <description>Hepatic fatty acid reesterification assessed by C11-palmitate PET</description>
          <units>micromol/ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.134" spread="0.056"/>
                    <measurement group_id="O2" value="0.091" spread="0.035"/>
                    <measurement group_id="O3" value="0.113" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Fatty Acid Uptake</title>
        <description>Hepatic fatty acid uptake assessed by C11-palmitate PET</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Fatty Acid Uptake</title>
          <description>Hepatic fatty acid uptake assessed by C11-palmitate PET</description>
          <units>micromol/ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.067"/>
                    <measurement group_id="O2" value="0.137" spread="0.051"/>
                    <measurement group_id="O3" value="0.155" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>VLDL-TG Secretion</title>
        <description>Hepatic VLDL-TG secretion assessed by [1-14C] VLDL tracer</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>VLDL-TG Secretion</title>
          <description>Hepatic VLDL-TG secretion assessed by [1-14C] VLDL tracer</description>
          <units>micromol/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="30"/>
                    <measurement group_id="O2" value="83" spread="49"/>
                    <measurement group_id="O3" value="71" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Whole Body Glucose Rd</title>
        <description>Whole body basal glucose metabolism assessed by [3-3H]glucose tracer kinetics</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin &quot;Sandoz&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Body Glucose Rd</title>
          <description>Whole body basal glucose metabolism assessed by [3-3H]glucose tracer kinetics</description>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.29"/>
                    <measurement group_id="O2" value="1.30" spread="0.31"/>
                    <measurement group_id="O3" value="1.78" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatty Acid Turnover</title>
        <description>Fatty acid turnover assessed as whole body C11-palmitate turnover</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Fatty Acid Turnover</title>
          <description>Fatty acid turnover assessed as whole body C11-palmitate turnover</description>
          <units>micromol/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" spread="127"/>
                    <measurement group_id="O2" value="476" spread="149"/>
                    <measurement group_id="O3" value="559" spread="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VLDL-TG Oxidation</title>
        <description>VLDL-TG oxidation assessed by 14C carbon dioxide (CO2) in exhaled breath</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>VLDL-TG Oxidation</title>
          <description>VLDL-TG oxidation assessed by 14C carbon dioxide (CO2) in exhaled breath</description>
          <units>percentage of 14C-VLDL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="5"/>
                    <measurement group_id="O2" value="30" spread="7"/>
                    <measurement group_id="O3" value="27" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 90 days trial</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Healthy Controls</title>
          <description>Healthy controls receiving 1000 mg metformin twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: 2 tablets twice daily in 3 months</description>
        </group>
        <group group_id="E3">
          <title>Metformin</title>
          <description>Metformin &quot;Teva&quot;, 1000 mg twice daily for 3 months&#xD;
Metformin: 1000 mg metformin twice daily in 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal uncomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractured vertebral column</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lars C. Gormsen, Consultant</name_or_title>
      <organization>Department of Nuclear Medicine &amp; PET Centre, Aarhus University Hospital</organization>
      <phone>004578456260</phone>
      <email>lars.christian.gormsen@clin.au.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

